Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yan Tu

Showing results (271-280 of 321) with videos related to

Pageof 33
Sort By:
Thoracic Cancer|April 19, 2022
Clinical outcomes of EGFR+/METamp+ vs. EGFR+/METamp- untreated patients with advanced non-small cell lung cancerKai-Cheng Peng, Jun-Wei Su, Zhi Xie, et al.
JTO Clinical and Research Reports|September 16, 2024
Combination of Cytologic Findings and Circulating Tumor DNA From Cerebrospinal Fluid Revealed SCLC Transformation in Patients With Leptomeningeal Metastases of Lung AdenocarcinomaJia-Xin Lin, Kai Yin, Li-Xu Yan, et al.
The New England Journal of Medicine|April 28, 2025
Zongertinib in Previously Treated <i>HER2</i>-Mutant Non-Small-Cell Lung CancerJohn V Heymach, Gerrina Ruiter, Myung-Ju Ahn, et al.
Translational Lung Cancer Research|September 29, 2021
The Chinese Thoracic Oncology Group (CTONG) therapeutic option scoring system: a multiple-parameter framework to assess the value of lung cancer treatment optionsJiu-Wei Cui, Qing Zhou, Shun Lu, et al.
Lung Cancer (Amsterdam, Netherlands)|September 13, 2025
Chinese expert consensus on perioperative management of patients with resectable anaplastic lymphoma kinase-fusion non-small cell lung cancerHai-Yan Tu, Chun Chen, Chang Chen, et al.
Journal of Translational Medicine|July 10, 2026
The effects of probiotics duration and type on immunotherapy efficacy in non-small cell lung cancer with or without antibioticsWei-Chi Luo, Zi-Jian Huang, Shi-Qi Mei, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 30, 2018
Strong Programmed Death Ligand 1 Expression Predicts Poor Response and De Novo Resistance to EGFR Tyrosine Kinase Inhibitors Among NSCLC Patients With EGFR MutationShan Su, Zhong-Yi Dong, Zhi Xie, et al.
Frontiers in Oncology|July 26, 2021
Afatinib in EGFR TKI-Naïve Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb StudiesAntonio Passaro, Filippo de Marinis, Hai-Yan Tu, et al.
Molecular Neurobiology|January 30, 2015
High Serum MiR-130a Levels Are Associated with Severe Perihematomal Edema and Predict Adverse Outcome in Acute ICHMeng-Die Wang, Yong Wang, Yuan-Peng Xia, et al.
Clinical Lung Cancer|June 6, 2022
Biomarker-Driven Studies With Multi-targets and Multi-drugs by Next-Generation Sequencing for Patients With Non-Small-Cell Lung Cancer: An Open-Label, Multi-center, Phase II Adaptive Umbrella Trial and a Real-World Observational Study (CTONG1702&CTONG1705)Si-Yang Maggie Liu, Hong-Hong Yan, Xue-Wu Wei, et al.
Pageof 33

Showing results (271-280 of 321) with videos related to

Sort By:
Pageof 33
Thoracic Cancer|April 19, 2022
Clinical outcomes of EGFR+/METamp+ vs. EGFR+/METamp- untreated patients with advanced non-small cell lung cancerKai-Cheng Peng, Jun-Wei Su, Zhi Xie, et al.
JTO Clinical and Research Reports|September 16, 2024
Combination of Cytologic Findings and Circulating Tumor DNA From Cerebrospinal Fluid Revealed SCLC Transformation in Patients With Leptomeningeal Metastases of Lung AdenocarcinomaJia-Xin Lin, Kai Yin, Li-Xu Yan, et al.
The New England Journal of Medicine|April 28, 2025
Zongertinib in Previously Treated <i>HER2</i>-Mutant Non-Small-Cell Lung CancerJohn V Heymach, Gerrina Ruiter, Myung-Ju Ahn, et al.
Translational Lung Cancer Research|September 29, 2021
The Chinese Thoracic Oncology Group (CTONG) therapeutic option scoring system: a multiple-parameter framework to assess the value of lung cancer treatment optionsJiu-Wei Cui, Qing Zhou, Shun Lu, et al.
Lung Cancer (Amsterdam, Netherlands)|September 13, 2025
Chinese expert consensus on perioperative management of patients with resectable anaplastic lymphoma kinase-fusion non-small cell lung cancerHai-Yan Tu, Chun Chen, Chang Chen, et al.
Journal of Translational Medicine|July 10, 2026
The effects of probiotics duration and type on immunotherapy efficacy in non-small cell lung cancer with or without antibioticsWei-Chi Luo, Zi-Jian Huang, Shi-Qi Mei, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 30, 2018
Strong Programmed Death Ligand 1 Expression Predicts Poor Response and De Novo Resistance to EGFR Tyrosine Kinase Inhibitors Among NSCLC Patients With EGFR MutationShan Su, Zhong-Yi Dong, Zhi Xie, et al.
Frontiers in Oncology|July 26, 2021
Afatinib in EGFR TKI-Naïve Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb StudiesAntonio Passaro, Filippo de Marinis, Hai-Yan Tu, et al.
Molecular Neurobiology|January 30, 2015
High Serum MiR-130a Levels Are Associated with Severe Perihematomal Edema and Predict Adverse Outcome in Acute ICHMeng-Die Wang, Yong Wang, Yuan-Peng Xia, et al.
Clinical Lung Cancer|June 6, 2022
Biomarker-Driven Studies With Multi-targets and Multi-drugs by Next-Generation Sequencing for Patients With Non-Small-Cell Lung Cancer: An Open-Label, Multi-center, Phase II Adaptive Umbrella Trial and a Real-World Observational Study (CTONG1702&CTONG1705)Si-Yang Maggie Liu, Hong-Hong Yan, Xue-Wu Wei, et al.
Pageof 33